Comparison of the efficacy and safety of 160 mcg ciclesonide administered once daily in the evening with or without different spacer types in patients with asthma

Trial Profile

Comparison of the efficacy and safety of 160 mcg ciclesonide administered once daily in the evening with or without different spacer types in patients with asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 04 May 2012 Company (Takeda Global Research and Development Center) added as reported by ClinicalTrials.gov.
    • 01 Nov 2009 Efficacy and tolerability results reported in Respiratory Medicine.
    • 24 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top